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Survival from upper gastrointestinal cancer is lar-
gely determined by stage at diagnosis, hence early
detection is key to improving outcomes in pa-
tients with this group of malignancies. The miss
rate for esophageal and gastric cancer at upper
gastrointestinal endoscopy is well document,
with studies reporting rates of 4% to 13% at index
endoscopy for cancers diagnosed on subsequent
investigations, including repeat endoscopy [1–6].
It is common to find views in the upper gastroin-
testinal tract impaired by mucus and bubbles.
That can hamper identification of subtle abnorm-
alities, such as dysplasia within Barrett’s esopha-
gus, or early gastric cancer. Several studies have
demonstrated that drinking a defoaming agent
before a procedure improves mucosal visibility
[7,8]. Results are conflicting among studies that
have examinedwhether the addition of amucoly-
tic such as N-acetylcysteine (NAC) to a defoaming
agent offers any further benefit [9–13].
The majority of studies to date have been carried
out in Asian populations. The only published
study in aWestern population of a pre-endoscopy
drink containing a defoaming agent and mucoly-
tic was performed by Neale et al in the UK [14].
In a pragmatic design with 2 control arms, they
compared no preparation with water alone, or a
solution of water/simethicone/NAC. The mean
volume of procedural flush required and propor-
tion of patients requiring use of flush was signifi-
cantly lower in the group that received the active
solution.
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Background and study aims: Mucosal views can
be impaired by residual bubbles and mucus dur-
ing gastroscopy. This study aimed to determine
whether a pre-gastroscopy drink containing si-
methicone and N-acetylcysteine improves muco-
sal visualisation.
Patients and methods: We conducted a random-
ized controlled trial recruiting 126 subjects un-
dergoing routine gastroscopy. Subjects were ran-
domized 1:1:1 to receive: A—pre-procedure drink
of water, simethicone and N-acetylcysteine
(NAC); B—water alone; or C—no preparation.
Study endoscopists were blinded to group alloca-
tion. Digital images were taken at 4 locations
(lower esophagus/upper gastric body/antrum/
fundus), and rated for mucosal visibility (MV)
using a 4-point scale (1=best, 4=worst) by 4 sep-
arate experienced endoscopists. The primary out-
come measure was mean mucosal visibility score
(MVS). Secondary outcomemeasures were proce-
dure duration and volume of fluid flush required
to achieve adequate mucosal views.
Results: Mean MVS for Group A was significantly
better than for Group B (1.35 vs 2.11, P<0.001)
and Group C (1.35 vs 2.21, P<0.001).
Mean flush volume required to achieve adequate
mucosal views was significantly lower in Group A
than Group B (2.0mL vs 31.5mL, P=0.001) and
Group C (2.0mL vs 39.2mL P<0.001). Procedure
duration did not differ significantly between any
of the 3 groups.
MV scores at each of the 4 locations demonstrated
significantly better mucosal visibility in Group A
compared to Group B and Group C (P<0.0025 for
all comparisons).
Conclusions: A pre-procedure drink containing si-
methicone and NAC significantly improves muco-
sal visibility during gastroscopy and reduces the
need for flushes during the procedure. Effective-
ness in the lower esophagus demonstrates poten-




This study (NICEVIS) was a randomized controlled clinical trial.
The primary objective was to determine whether water plus si-
methicone and NAC, given as a pre-endoscopic drink, improved
mucosal visualization compared to an unprepared upper gastro-
intestinal tract or one prepared with water alone. The trial was
registered with the European Clinical Trials agency (EudraCT
2013-001097-24), and approved by the local research ethics
committee (13/SC/0248). The study was conducted between July
2013 and March 2014.
Inclusion and exclusion criteria
Patients referred for routine or urgent outpatient upper gastroin-
testinal endoscopy with a minimum age of 18 years were eligible
for inclusion. Predefined exclusion criteriawere as follows: emer-
gency cases, patients who would already receive NAC/simethi-
cone pre-endoscopy as part of their standard care, patients with
a known stricture, pregnant or breastfeeding women, known up-
per gastrointestinal malignancy, pharyngeal weakness/paralysis
bulbar or pseudobulbar palsy, previous oesophageal or gastric
surgery and known allergy to NAC or simethicone.
Baseline patient data on age, gender, medication usage (particu-
larly gastrointestinal medications) were recorded.
Randomization and study procedures
Patients were randomized to 3 groups:-
▶ Group A–Simethicone/NAC pre-endoscopy drink (50mL
water, 1000mg N-acetylcysteine, 60mg simethicone)
▶ Group B–50mL water pre-endoscopy drink
▶ Group C–no pre-endoscopy drink (current standard practice)
Randomization was performed by random sequence generation
in permuted blocks of varying sizes by an independent statisti-
cian. Allocations were placed in sealed envelopes to be opened
by the nurse preparing the pre-endoscopy drink.
The pre-endoscopy drink was given 5 to 10 minutes before the
procedure and subjects were asked to roll onto their left and right
sides briefly to aid coverage of the gastric mucosa.
The endoscopist was blinded to the preparation used. Following
intubation excess fluid in the stomachwas removed via the endo-
scope suction channel. Electronic photographs were taken at 4
predefined locations (Lower oesophagus/Upper body greater
curve/Antrum/Fundus) during the procedure, prior to any muco-
sal flushing. Images were digitally stored for subsequent mucosal
visibility scoring.
Fluid flushes of the simethicone/NAC solution were then used to
remove residual mucus/foam to achieve adequate mucosal views.
The volume of flushes required and the total procedure duration
were recorded.
Photographs were rated for mucosal visibility by 4 experienced
endoscopists (scorers). Visibility scores were rated on a 4-point
scale (●" Fig.1):
1. No adherent mucus and clear views of the mucosa
2. A thin coating of mucus that did not obscure views of the
mucosa
3. Some mucus/bubbles partially obscuring views of the mucosa
(a small mucosal lesion might be missed without flushing).
4. Heavy mucus/bubbles obscuring views of the mucosa (a small
mucosal lesion could easily be missed without flushing)
Therefore the total score based on 4 photographs ranged from 4
(best) to 16 (worst). The scorers were trained in the use of the vis-
ibility score with photographic examples prior to scoring the
study photographs. A pre-study test was performed to check
that there was sufficient interobserver agreement before the
study photographs were scored with a prespecified kappa value
of >0.4 required before the study images could be rated. The scor-
ers were blinded to the pre-endoscopy preparation relating to
each photograph. The mean visibility scores for the 3 groups
were compared.
Fig.1 Mucosal visibility score examples; a fundus
view score 1, b fundus view score 2, c fundus view
score 3, d antrum view score 4.
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Primary and secondary endpoints
The primary endpoint was mean total mucosal visibility score at
4 predefined locations rated by 4 blinded assessors. Secondary
endpoints were: 1) volume of fluid flushes required to achieve
adequate mucosal views; and 2) total procedure time.
Statistics and sample size calculation
Based on the results of similar previous studies, we expected the
mean score in Groups B and C to be 8.2 with a standard deviation
of 2.7. The standard deviation of Group Awas expected to be 1.2.
We aimed to be able to detect a 20% improvement in overall vis-
ibility score. Working with a significance level of 0.017 to allow
for multiple comparisons between the 3 groups and a power of
80%, a sample size of 40 patients in each group (120 in total)
was required. To allow for missing or spurious data occurring in
5% of cases, the sample size was increased to 126 (42 patients per
group).
Interobserver agreement was calculated using mean weighted
Fleiss’s kappa. Mean total mucosal visibility scores between
groups were compared using one-way analysis of variance with
Tukey’s test to detect between group differences. In post-hoc
testing the Chi-squared test was used to compare the proportion
of images with inadequate visibility scores (score 3 or 4) between
groups. Procedure duration and mean flush volume were com-





A total of 126 patients were enrolled and randomized to the 3
study groups. Three patients were excluded as their procedure
could not be completed and 1 was excluded as severe esophagitis
was found (●" Fig.2). In a further 2 patients 1 of the 4 study pho-
tographs was not captured due to technical reasons. The remain-
ing 3 study photographs for each of these participants were in-
cluded for analysis.
One further patient was excluded from the analysis for procedure
duration and flush volume because of actively bleeding angiodys-
plasia that required endoscopic intervention.
Baseline group demographics
The 3 study groups were well matched in terms of baseline de-
mographics and indications for endoscopy (●" Table1). A signifi-
cant difference was found between groups in the number of pa-
Group A  





Completed group A  
n = 41
Completed group B 
n = 40
Completed group C  
n = 41 
Excluded group A  
n = 1 (incomplete 
procedure)
Excluded group B  
n = 2 (incomplete 
procedure)
Excluded group C  
n = 1 (severe 
oesophagitis)
Randomised, n = 126 
Fig.2 Study enrolment and exclusions flow chart.
Table 1 Baseline demographics, indications for endoscopy, significant regular medications, relevant comorbidities and procedural medications.








n (%) 22 (53.7) 20 (50.0) 20 (48.8) 0.90
Age (Years)
mean (SD) 63.8 (15.8) 62.3 (15.4) 61.9 (16.2) 0.84
Indication –n
Dyspepsia/heartburn 21 22 13 0.10
Dysphagia  4  7 13 0.04
Anaemia  6  4  5 0.80
Barrett’s surveillance  7  6  8 0.84
Weight loss  2  4  2 0.59
Duodenal biopsies ( + ve TTG)  1  1  1 1.00
Abnormal radiology  1  0  0 0.37
Ulcer healing check  1  0  4 0.07
Other  5  9  4 0.26
Regular medication –n
PPI/H2RA 31 27 30 0.61
Prokinetic  5  2  4 0.50
Calcium channel antagonist  9  6  6 0.60
Comorbidities– n
Type 1 Diabetes  2  0  0 0.13
Type 2 Diabetes  5  5  6 0.93
Gastroparesis  0  0  1 0.37
Procedural medication –n
Throat spray 33 30 29 0.59
Sedation 19 23 26 0.31
PPI, proton pump inhibitor; H2RA, histamine 2 receptor antagonist
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tients referred for investigation of dysphagia (P=0.04), but not for
any other indications for gastroscopy.
Use of medications that may affect gastric fluid secretion or gas-
tric emptying (PPI, H2RA, prokinetics and calcium-channel an-
tagonists) did not differ significantly between the 3 groups. There
were also no significant differences in the prevalence of condi-
tions that may affect gastric emptying (diabetes mellitus, gastro-
paresis).
Interobserver agreement prior to rating study images
80 non-study imageswere used to ensure adequate inter-observ-
er agreement when using the 4-point mucosal visibility rating
scale prior to rating of the study images. Themeanweighted kap-
pa value between the 4 assessors was 0.583.
Mucosal visibility scores
Analysis of the primary outcome measure of mean total mucosal
visibility score (TMVS) showed significant differences between
groups. Mucosal visibility was significantly better in Group A
compared to Groups B and C (P<0.001 for both comparisons).
No significant difference in mean TMVS was found between
Groups B and C (P=0.541) (●" Table2).
Subanalysis of the results for each of the 4 predefined locations
showed very similar results, with significantly better mean visi-
bility score for each of the 4 locations in Group A compared to
Groups B/C and no significant difference in mean score between
Groups B and C.
The results of post-hoc testing was carried out to assess the dis-
tribution of mucosal visibility scores between groups are shown n
●" Table3.
Significant differences were found between Groups A and B and
Groups A and C in the distribution of mucosal visibility scores
(P<0.001). In Group A, 96% of images were rated as not requir-
ing additional use of flushing to achieve adequate views, com-
pared to 68.2% in Group B and 68.3% in Group C.
The mean weighted kappa for the study images was 0.605, indi-
cating good interobserver agreement [15].
Procedure duration and volume of flush used
No significant differences in mean procedure duration between
the 3 groups were found (●" Table4). In Group A, a trend towards
shorter procedure duration was seen but it did not reach statisti-
cal significance.
Mean flush volume required to achieve mucosal views during
gastroscopy was 2mL for Group A compared to 31.5mL for Group
B and 39.2mL for Group C. The difference in mean volume be-
tween Groups A and B and also Groups A and C were highly sta-
tistically significant (●" Table4). No significant difference in flush
volume was found between Groups B and C.

















Upper body 1.18 (1.09–1.28) 1.69 (1.48–1.89) 1.93 (1.66–2.21) 0.002 < 0.001 0.210
Antrum 1.58 (1.39–1.77) 2.34 (2.11–2.57) 2.36 (2.10–2.62) < 0.001 < 0.001 0.992
Fundus 1.20 (1.09–1.30) 2.31 (2.02–2.60) 2.40 (2.08–2.71) < 0.001 < 0.001 0.869
Total 1.45 (1.27–1.63) 2.10 (1.90–2.30) 2.16 (1.92–2.40) < 0.001 < 0.001 0.914
5.40 (5.02–5.80) 8.44 (7.91–8.97) 8.85 (8.17–9.53) < 0.001 < 0.001 0.541
Table 3 Distribution of mucosal visibility scores.








1 459 (70.4%) 176 (27.7%) 162 (24.7%)
2 167 (25.6%) 258 (40.6%) 286 (43.6%)
3  16 (2.5%) 160 (25.2%) 115 (17.5%)
4  10 (1.5%)  42 (6.6%)  93 (14.2%)
Images rated as inadequate prep (3 /4)–n (%)  26 (4.0%) 202 (31.8%) 208 (31.7%) A vs B < 0.001
A vs C < 0.001
B vs C 0.983
Total image scores–n 652 636 656
Table 4 Procedure duration and volume of intraprocedural flush required.













(+ /–SD)– seconds 309 (+ /– 129) 352 (+ /– 216) 334 (+ /– 118) 0.438 0.758 0.863
Flush volume, mean (+ /–SD)–mL   2.0 (+ /– 9.3)  31.5 (+ /– 38.3)  39.2 (+ /– 45.4) 0.001 < 0.001 0.583




One serious adverse event (AE) occurred during the study. A par-
ticipant who received water pre-procedure developed laryngos-
pasm shortly after intubation of the esophagus. The procedure
was abandoned and the participant recovered quickly with no
long-term sequelae. Independent review considered this to be
unrelated to the water administered pre-procedure.
Discussion
This randomized controlled trial examined the impact of a pre-
gastroscopy drink containing the mucolytic agent N-acetylcys-
teine and defoaming agent simethicone on mucosal visibility
during routine outpatient gastroscopy. Two control groups were
used, 1 that receiving water and the other that received no prep-
aration. The endoscopists performing study procedures and the 4
separate endoscopists who assessed the study images were all
blinded to group allocation. The active study medication was
well tolerated by all participants and did not result in any AEs or
reactions.
Analysis of the primary outcome showed significant improve-
ment in mucosal visibility in the group receiving the active study
medication compared to both control groups. Hence the findings
of this study are in keeping with those of several previous studies
demonstrating improvements in gastric mucosal visibility with a
pre-gastroscopy drink containing a mucolytic and a defoaming
agent [9,10,14]. This is the first study to specifically assess the ef-
fect of the combination of simethicone and NAC on the quality of
mucosal visibility in a Western population. In a post-hoc analysis
only 4% of images in the group receiving the active study medi-
cation were deemed to show inadequate mucosal visibility com-
pared to 32% in the water and no preparation groups. This study
was not designed to determine whether the addition of NAC of-
fers any benefit over simethicone and water alone.
Secondary outcome measures demonstrated a marked reduction
in the volume of flush required to achieve adequate mucosal
views in the group receiving the active pre-gastroscopy drink.
We hypothesized that reduced need for flushes may reduce pro-
cedure time, but although there was a trend towards reduced
time in Group A, it did not reach significance. That may be due
to confounding factors such as indication for endoscopy and
findings during the procedure. Barrett’s surveillance cases tend
to result in a longer procedure time due to the need to carefully
assess the Barrett’s mucosa and take multiple biopsies. However
the proportion of Barrett’s cases was similar in the 3 study
groups. A larger study may have sufficient statistical power to
show a significant difference in procedure time between the
groups. While no significant difference in procedure time was
demonstrated, it can be argued that for subjects in Group A
more time could be spent carefully assessing a mucosal surface
that was free of mucus and bubbles. In contrast in Groups B & C
some of the procedure time would be spent flushing the mucosal
surface before adequate views could be achieved, thus reducing
the amount of procedure time utilized for careful mucosal in-
spection.
The importance of adequate bowel cleansing preparation prior to
colonoscopy is well understood and numerous studies have dem-
onstrated the importance of good bowel preparation to improve
adenoma detection [16–19]. In contrast, at least in the West, the
concept of giving preparation prior to gastroscopy is not familiar
to most endoscopists and pre-procedure “gastric prep” is not
part of routine care. In a nationwide survey, no UK endoscopy
units were routinely using a mucolytic drink prior to gastroscopy
[20]. Adequate preparation prior to gastroscopy is now of even
greater importance than in previous years; with improved endo-
scopic technology, enhancement techniques, and training,
endoscopists can detect and remove subtle precancerous lesions
and early cancer. However, for that to be possible, good views of
the mucosal surface are paramount.
Whereas previous studies of pre-endoscopy preparatory drinks
have demonstrated improvement in gastric mucosal visibility,
this is the first study to demonstrate improved mucosal visibility
in the lower esophagus. This is a vital area for careful inspection
during gastroscopy, particularly as the incidence of esophageal
adenocarcinoma and gastro-oesophageal junction adenocarcino-
ma has risen rapidly in the UK in recent years. Early dysplastic le-
sions arising in Barrett’s oesophagus, the precursor of esophageal
adenocarcinoma, can be subtle and easily missed, hence clear
views of this particular area of the upper gastrointestinal tract
are vital.
There are of course downsides to giving a pre-gastroscopy drink:
Time to prepare the drink may lengthen the overall time to com-
plete the procedure. In practice it takes 2 to 3 minutes for a nurse
to prepare and administer the drink. In this study the drink was
given 5 to 10 minutes prior to the procedure, which led to a fur-
ther delay while waiting for the drink to take effect. With careful
planning, however, patients could be administered the drink in
advance of entering the endoscopy suite. There are also cost im-
plications. At current prices the drink costs £1.21 per patient. A
busy endoscopy unit such as ours performs around 6,000 gastro-
scopies per annum, whichwould result in additional annual costs
of around £7,000.
The main concerns regarding safety of administering a drink
prior to endoscopy are those of potential aspiration of fluid. In
this study no patient developed aspiration and no AEs related to
study medication occurred. Similarly none have been reported in
other similar studies.
The ideal outcome measure for any study of this type would be
detection of neoplasia, and ideally early upper gastrointestinal
neoplasia where curative treatment is still possible. However,
given the low rate of neoplasia detection in patients attending
for diagnostic gastroscopy, such a study would require many
thousands of participants to demonstrate a significant benefit.




In summary this study confirms that a pre-gastroscopy drink
containing simethicone and NAC significantly improves mucosal
visibility in the lower esophagus and stomach and reduces the
need for procedural flushing. This has the potential to become
part of standard pre-gastroscopy preparation to improve the de-
tection of upper gastrointestinal neoplasia.
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